Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Viola W Zhu

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Lung Cancer (Auckland, N.Z.)|July 21, 2021
Spotlight on Mobocertinib (TAK-788) in NSCLC with <i>EGFR</i> Exon 20 Insertion MutationsShannon S Zhang, Viola W Zhu
JTO Clinical and Research Reports|September 30, 2021
Catalog of 5' fusion partners in <i>RET+</i> NSCLC Circa 2020Sai-Hong Ignatius Ou, Viola W Zhu
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcomeSai-Hong Ignatius Ou, Viola W Zhu
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Liquid Biopsy to Identify Actionable Genomic AlterationsSai-Hong Ignatius Ou, Misako Nagasaka, Viola W Zhu
JTO Clinical and Research Reports|September 30, 2021
Catalog of 5' Fusion Partners in <i>ALK</i>-positive NSCLC Circa 2020Sai-Hong Ignatius Ou, Viola W Zhu, Misako Nagasaka
Trends in Cancer|November 19, 2019
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung CancerViola W Zhu, Samuel J Klempner, Sai-Hong Ignatius Ou
Lung Cancer (Amsterdam, Netherlands)|June 27, 2021
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLCShannon S Zhang, Misako Nagasaka, Viola W Zhu, et al.
Lung Cancer (Auckland, N.Z.)|March 19, 2019
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with <i>EGFR</i>-mutant non-small cell lung cancer and emergent <i>MET</i> amplificationViola W Zhu, Alexa B Schrock, Siraj M Ali, et al.
Translational Oncology|August 8, 2021
Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?Sai-Hong Ignatius Ou, Misako Nagasaka, Danielle Brazel, et al.
Clinical Neurology and Neurosurgery|May 2, 2017
A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)Viola W Zhu, Sanjay Hinduja, Stevan R Knezevich, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Lung Cancer (Auckland, N.Z.)|July 21, 2021
Spotlight on Mobocertinib (TAK-788) in NSCLC with <i>EGFR</i> Exon 20 Insertion MutationsShannon S Zhang, Viola W Zhu
JTO Clinical and Research Reports|September 30, 2021
Catalog of 5' fusion partners in <i>RET+</i> NSCLC Circa 2020Sai-Hong Ignatius Ou, Viola W Zhu
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcomeSai-Hong Ignatius Ou, Viola W Zhu
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Liquid Biopsy to Identify Actionable Genomic AlterationsSai-Hong Ignatius Ou, Misako Nagasaka, Viola W Zhu
JTO Clinical and Research Reports|September 30, 2021
Catalog of 5' Fusion Partners in <i>ALK</i>-positive NSCLC Circa 2020Sai-Hong Ignatius Ou, Viola W Zhu, Misako Nagasaka
Trends in Cancer|November 19, 2019
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung CancerViola W Zhu, Samuel J Klempner, Sai-Hong Ignatius Ou
Lung Cancer (Amsterdam, Netherlands)|June 27, 2021
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLCShannon S Zhang, Misako Nagasaka, Viola W Zhu, et al.
Lung Cancer (Auckland, N.Z.)|March 19, 2019
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with <i>EGFR</i>-mutant non-small cell lung cancer and emergent <i>MET</i> amplificationViola W Zhu, Alexa B Schrock, Siraj M Ali, et al.
Translational Oncology|August 8, 2021
Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?Sai-Hong Ignatius Ou, Misako Nagasaka, Danielle Brazel, et al.
Clinical Neurology and Neurosurgery|May 2, 2017
A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)Viola W Zhu, Sanjay Hinduja, Stevan R Knezevich, et al.
Pageof 5